Literature DB >> 18357376

Exploration of the mechanism underlying the tumor necrosis avidity of hypericin.

Marie Van de Putte1, Yicheng Ni, Peter A M De Witte.   

Abstract

Hypericin, a potent necrosis avid agent, features a peculiar affinity for necrotic tissue. Necrosis avid contrast agents have been investigated as markers for non-invasive imaging of different disorders. In view of the promising clinical applications, a more complete knowledge of the mechanism of action is important for the future development of new chemical structures with improved characteristics. To study whether a compound-specific or non-specific mechanism based on plasma lipoprotein transport is involved in the accumulation of hypericin in intratumoral necrosis, we performed a visual and quantitative fluoromicroscopic analysis of the colocalization of hypericin and DiOC18-labeled lipoproteins in subcutaneous murine radiation-induced fibrosarcoma tumors. Microscopic fluorescent overlay images of necrotic tumors demonstrated that hypericin already showed clear necrosis avid characteristics 4 h after injection, whereas a similar outstanding accumulation in necrosis was not demonstrated for the labeled lipoproteins. Moreover, a quantitative analysis of fluoromicroscopic images of tumor necrosis at 24 h after injection showed differences in normalized fluorescence intensities between hypericin and labeled lipoproteins of 50-100%, reflecting a shifted pattern in localization. We conclude that our results are indicative of a release of hypericin from the lipoprotein complex at some point along its way through the peri-necrotic tumor area and the necrotic tissue debris, which is in line with the hypothesis of a compound-specific mechanism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18357376

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  15 in total

1.  Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy.

Authors:  Thierry Marysael; Matthias Bauwens; Yicheng Ni; Guy Bormans; Jef Rozenski; Peter de Witte
Journal:  Invest New Drugs       Date:  2011-12-21       Impact factor: 3.850

2.  Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors.

Authors:  Thierry Marysael; Yicheng Ni; Evelyne Lerut; Peter de Witte
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-21       Impact factor: 4.553

Review 3.  The recent progress of the mechanism and regulation of tumor necrosis in colorectal cancer.

Authors:  Xi Zhang; Lirong Chen
Journal:  J Cancer Res Clin Oncol       Date:  2015-06-21       Impact factor: 4.553

Review 4.  A review on various targeted anticancer therapies.

Authors:  Junjie Li; Feng Chen; Marlein Miranda Cona; Yuanbo Feng; Uwe Himmelreich; Raymond Oyen; Alfons Verbruggen; Yicheng Ni
Journal:  Target Oncol       Date:  2012-02-15       Impact factor: 4.493

5.  Radioiodinated hypericin as a tracer for detection of acute myocardial infarction: SPECT-CT imaging in a swine model.

Authors:  Shuping Yang; Junting Ma; Tian Li; Peng Wang; Xudan Wang; Jian Zhang; Yicheng Ni; Haibo Shao
Journal:  J Nucl Cardiol       Date:  2022-03-16       Impact factor: 5.952

Review 6.  Biomarkers and molecular probes for cell death imaging and targeted therapeutics.

Authors:  Bryan A Smith; Bradley D Smith
Journal:  Bioconjug Chem       Date:  2012-09-26       Impact factor: 4.774

7.  A single-dose toxicity study on non-radioactive iodinated hypericin for a targeted anticancer therapy in mice.

Authors:  Jun-jie Li; Marlein Miranda Cona; Yuan-bo Feng; Feng Chen; Guo-zhi Zhang; Xue-bin Fu; Uwe Himmelreich; Raymond Oyen; Alfons Verbruggen; Yi-cheng Ni
Journal:  Acta Pharmacol Sin       Date:  2012-10-29       Impact factor: 6.150

8.  Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications.

Authors:  Junjie Li; Raymond Oyen; Alfons Verbruggen; Yicheng Ni
Journal:  J Cancer       Date:  2013-01-22       Impact factor: 4.207

Review 9.  Necrosis avidity: a newly discovered feature of hypericin and its preclinical applications in necrosis imaging.

Authors:  Binghu Jiang; Jichen Wang; Yicheng Ni; Feng Chen
Journal:  Theranostics       Date:  2013-08-10       Impact factor: 11.556

10.  Exploring theranostic potentials of radioiodinated hypericin in rodent necrosis models.

Authors:  Junjie Li; Marlein Miranda Cona; Feng Chen; Yuanbo Feng; Lin Zhou; Jie Yu; Johan Nuyts; Peter de Witte; Jian Zhang; Uwe Himmelreich; Alfons Verbruggen; Yicheng Ni
Journal:  Theranostics       Date:  2012-10-18       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.